TOGETHER. ALL THE WAY"





TROUBLESHOOTING: MEDIA IN THE IVF LABORATORY

Brett Glazar, M.S. Senior Embryologist, Research Vitrolife



DISCLOSURES

- Vitrolife employee
- Vitrolife is a international manufacturer and distributor of ART medical devices, including (not limited to) culture media, disposable plastic and glass devices, lasers and time-lapse imaging and incubation systems.





Background


Manufactures Responsibilities

Troubleshooting Basics

Conclusions



STAKE HOLDERS IN IVF CHAIN OF CUSTODY BLAME CHAIN








	Clinician	Laboratory	Clinician					
Efficacy	95% respond to stimulation		A subset of embryos implant					
IVF Steps	Oocyte/ Stimulation Retrieval	Oocyte/ Sperm Selection	Early Transfer Pregnancy Support Testing					
	??? variables	Variables > 200 variables	??? variables					

Montag, M. ESHRE Symposium 2016 (Reproduced with permission of author)


Vitrolife **7**

REALITY





IMPACT OF STRESS




Preimplantation Embryo Development

Cumulative Stress







Vitrolife **7**

Good Manufacturing Practice for medical devices
 – FDA Code of Federal Regulations; Title 21, Part 820

"to govern the methods used in and the facilities and controls used for the design, manufacture, packaging, labeling, storage, installations, and servicing for all finished medical devices intended for human use".

- ISO 13485:2008 Medical devices Quality Management Systems Requirements for regulatory purposes
- ISO 9001:2008 Quality Management Systems Requirements
- CAN/CSA 13485:2008

DOCUMENTATION QUALITY MANAGEMENT

- Receiving records
- Personnel training
- Purchasing/Distribution
- Manufacturing record
- QC/MEA
- Certificate of Analysis
- Customer Service

Vitrolife 🗖

Vitrolife **7**

CERTIFICATE OF ANALYSIS

G-TL™

REF	CONTENT	LOT	EXPIRY DATE
10145	1x30 mL	506667	2017-10-20

INDICATION FOR USE

Medium for culture of embryos from fertilisation to the blastosyst stage

Caution: Federal (US) law restricts this device to sale by or on the order of a physician or practitioner trained in its use.

DESCRIPTION

Bicarbonate buffered medium containing hyaluronan and human serum albumin.

APPLICATION

For use after equilibration at 37°C and 6% CO2.

RAW MATERIALS

The raw materials were tested and evaluated by stringent quality control procedures.

COMP	nsi	тіс	M
COMP	03		

Alanine	Alanyl-glutamine	Arginine	Asparagine
Aspartate	Calcium chloride	Calcium pantothenate	Cystine
EDTA	Gentamicin	Glucose	Glutamate
Glycine	Histidine	Human serum albumin*	Hyaluronan
Isoleucine	Leucine	Lysine	Magnesium sulphate
Methionine	Phenylalanine	Potassium chloride	Proline
Pyridoxine	Riboflavin	Serine	Sodium bicarbonate
Sodium chloride	Sodium citrate	Sodium dihydrogen phosphate	Sodium hydroxide
Sodium lactate	Sodium pyruvate	Taurine	Thiamine
Threonine	Tryptophan	Tyrosine	Valine
Water for injection (WFI)			

*Pharmaceutical infusion-grade for medical use, free from HBV, HCV and HIV.

PRODUCT PROPERTIES	SPECIFICATION	RESULT
pH (at +37°C and 6 % CO2 atmosphere)	7.30±0.10	7.32
Osmolality [mOsm/kg]	270±5	270
Sterility Assurance Level (sterile filtration)	1E-3	1E-3
Bacterial endotoxins (LAL assay) [IU or EU/mL]	<0.25	<0.25
Mouse embryo assay (1-cell)[% expanded blastocyst within 96h]	>=80	>=80
Mouse embryo assay (1-cell)[blastocyst cell number within 96h]	No statistical	PASS

¹ Mean cell number of the test group is statistically compared to the control group. The mean of the test group must not be statistically different (P>0.05) to the control to constitute a Pass.

2017-06-30 Camilla Johansson Quality Control Manager

MANUFACTURERS DEVIATIONS

FDA CFR Title 21, Part 820.198 sub-part M:

- Each manufacturer shall maintain complaint files.
- Each manufacturer shall establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit. Such procedures shall ensure that:
 - (1) All complaints are processed in a uniform and timely manner;
 - (2) Oral complaints are documented upon receipt; and
 - (3) Complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA.



MANUFACTURERS OBLIGATIONS

Media Manufacturing must:

- Comply with 510(k)
- Comply with GMP
- Comply with QMS
 - Requires detail documentation
 - Changes/Deviations reported (internally/externally)
 - Reregistration as required per FDA (Significant technology or safety modifications- See FDA)



The root cause of *most* culture media complaints are not related to the media itself.

Generally there are other factors that caused the observations

- Transport
- Handling
- Disposables





TROUBLESHOOTING IN THE LAB- MEDIA



TROUBLESHOOTING FACTORS

QC and QA:

- · Identify possible toxins in the laboratory
- Maintain/improve efficacy

Oxygen concentration: • Reduce to <10% • Include antioxidants in media

Tissue Culture Ware:

- Emission of VOCs
- Appropriate QC to avoid embryo toxicity

Albumin:

Blood-derived albumin may contain phthalates
Role for recombinant albumin for safety and standardization

Number & type of Incubators:

Static Culture:

- · Leads to changes in medium composition
- Creation of unstirred layers
- Toxin build-up

Number of Embryos & Drop Volume: • Impacts efficacy of embryo derived factors

Oil overlay:

 Reduce shifts in pH & provide greater temperature stability

Pipetting:

· Effects on pH and temperature stability

- Minimize number of manipulations
- Use of the slowest speed with gentle pipetting action

Isolettes:

Maintain constant pH & temperature stability
Provides barrier to VOCs

Air quality:

- Monitor frequently
- Off-gas plastic ware if required
- Use of appropriate filtration

Light: • Minimize exposure

Vitrolife 🔨


TROUBLESHOOTING ROOT CAUSE ANALYSIS

Methods for RCA:


- Brainstorming
- 5 "Why's"
- Flowcharting
- Fishbone diagrams
- Affinity diagrams

Must be:

- Organized
- Thorough
- Logical







Vitrolife 🔨


TROUBLESHOOTING IDENTIFYING THE PROBLEM







TROUBLESHOOTING STRATEGY FOR RCA



Observations

Confirmation

Risk Assessment

Investigation

Root Cause

CAPA

Follow-up

Vitrolife 🔨




What's the Goal:


Identify <u>all</u> possible factors influencing the observations

What happened
How it happened
Why it happened...so that
Actions for preventing reoccurrence are developed





Vitrolife 🔨



Vitrolife 🔨

Staff

- Background
- Proficiency
- Observation
- Communication

Quality Management System

KPIs

- Strategy
- Internal Notification
- External Notification



QC Review

- Verify Control materials:
 - LOT #
 - REF #
- Verify methods:
 - Procedures
 - Equipment
 - Environment

Activity:


- Matrix of data
 - all LOT# used
 - All personnel
 - Look for changes
 - Identify unique observations



Material	Dish Operator	C/O Operator	Incubator	Hyaluronidase	OVOIL	Protein	Dish	G-MOPS+	Results
RM #1	BG	ES	191	XXXXXX	ABABAA	12311	20180101	SSSSSS	Pass
RM #2	BG	ES	191	XXXXXX	ABABAA	12311	20180101	SSSSSS	Pass
RM #3	KD	ES	191	XXXXXX	ABABAA	12311	20180101	SSSSSS	Pass
RM #4	KD	ES	191	XXXXXX	ABABAA	12311	20180101	SSSSSS	Pass
FP #1	BG	ES	191	XXXXXX	ABABAA	12311	20180101	SSSSSS	Pass
FP #2	BG	ES	191	XXXXXX	ABABAA	12311	20180101	SSSSSS	Pass
FP #3	BG	ES	191	ААААА	ABABAA	12311	20180101	SSSSSS	Fail
FP #4	BG	ES	191	ААААА	ABABAA	12311	20180101	SSSSSS	Fail

Vitrolife **7**

TROUBLESHOOTING ROOT CAUSE



Vitrolife 🔨

TROUBLESHOOTING ROOT CAUSE

Smoking gun

- Media was contaminated
- Incubator humidity pans ran dry
- CO2 runs out
- Clinical deviations
- Sally was sick and was coughing in the incubator
- Construction in building

Lab Fairies

- It just went away!



TROUBLESHOOTING ROOT CAUSE

Human error is never commonly identified as the root cause

Often there are other identifiable cause:

- Lack of training
- Procedure
- Neglect
- ...



TROUBLESHOOTING CAPA

Corrective Action: Action taken to immediately limit or correct the results of the identified problem. Risk mitigation?

Replace the contaminated media

Preventative Action: Actions taken to ensure the problem isn't repeated.

 Change procedure to prevent contamination from happening (add PPE or stop supplementing product off label)



TROUBLESHOOTING FOLLOW-UP

Internal

- Review of the issue following CAPA
- Evaluate the effect of the preventative actions
- Evaluate the effect of corrective actions eff
- Has it happened again?

External

- Contact clinical staff
- Contact manufacturers
- If it's a determined to be a notifyable problem the manufacturer is obligated to perform investigation, including CAPA and regulatory notification, per FDA.

CONCLUSION

- Troubleshooting is a complex but critical activity
- Variation in results can impact clinical outcomes
- Many variable are in play, so troubleshooting needs to be organized
 - There can be more than one cause
- Manufacturers are:
 - Responsible for controlling their processes
 - Required to report customer observation and evaluate the severity
- The goal is to discover the root cause and follow up!
- Sometimes the initial suspected causes opens other doors!

REFERENCES

- Gardner, D.K., Lane, M., 2003. Towards a single embryo transfer. Reprod. Biomed. Online 6, 470–481.
- Wale, P.L., Gardner, D.K., 2016. The effects of chemical and physical factors on mammalian embryo culture and their importance for the practice of assisted human reproduction. Hum Repro Update, Vol.22, No.1 pp. 2–22, 2016.
- Elder K et al. (2015) Troubleshooting and Problem-Solving in the IVF Laboratory. Cambridge University Press.





